Key clinical point: Ocrelizumab is effective and safe in patients with relapsing-remitting multiple sclerosis who had inadequate responses to previous disease-modifying treatments.
Major finding: The adjusted annualized relapse rate in this cohort was 0.065 with 48 weeks of follow-up.
Study details: A phase 3B study including 608 patients with relapsing-remitting multiple sclerosis who had inadequate response to disease-modifying treatment.
Disclosures: Dr. Leist reported disclosures related to Alkermes, Bayer, Biogen, EMD Serono, Genentech, Inc., Novartis, Sanofi Genzyme, Sun Pharma, and Teva Neuroscience.
Leist TP, et al. Presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, May 4-10, 2019. Philadelphia. Presentation S56.007.